Table II.

Frequency of the Arg753Gln SNP among patients suffering from LD

PatientsArg753Gln n(%)All ControlsaMatched ControlsMatched Groups
n (%)ORb 95% CIpcn (%)OR 95% CIp Valuen (%)OR 95% CIp
Total 9 42 0.459 0.0369 21 0.393 0.0331 NDNDND
(n = 155) (5.8) (12.0) 0.21–0.95 (13.5) 0.17–0.89
Stage I0420.1320.0570210.1140.083540.0950.1110
(n = 27)(0)(12.0)0.01–2.19(13.5)0.01–2.24(14.8)0.01–1.86
Stage II7421.5510.317211.3540.612761.2021.0
(n = 40)(17.5)(12.0)0.64–3.73(13.5)0.53–3.45(15)0.37–3.96
Stage III 2 42 0.170 0.0047 21 0.148 0.0028 11 0.163 0.0179
(n = 88) (2.3) (12.0) 0.04–0.72 (13.5) 0.03–0.65 (12.5) 0.04–0.76
  • a Population size, n = 349.

  • b All statistics were performed with GraphPad Prism software.

  • c Values of p were determined using a two-sided Fisher exact test. Significant results are printed in bold.